Peptide
ARA-290
SaveAn 11-amino-acid peptide derived from erythropoietin that activates the innate repair receptor without erythropoietic activity, studied for neuropathy and tissue repair.
Quick verdict
Promising phase II data for sarcoidosis-related neuropathy and diabetic neuropathy. Development has been slow and no product is approved.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Multiple small phase II trials in neuropathic pain and sarcoidosis show modest benefit. Larger confirmatory trials have not been completed.
Benefits
- Reduced neuropathic symptoms in phase II sarcoidosis trial
- Tissue-protective without erythropoietic side effects
- Anti-inflammatory properties in preclinical models
Dosage notes
Clinical trials used 2–8 mg subcutaneously. No commercial dosing established.
Side effects
- Injection-site reactions
- Headache
- Generally well tolerated in short-term trials
Who should be cautious
Investigational compound. Not approved in any jurisdiction for clinical use.
What this page cannot tell you
Phase II results are encouraging but sample sizes are small. No phase III data exist.
Leaderboard scores
- Pain35
- Recovery30
Write a review
Sign in to write a review.